Larimar Therapeutics (LRMR) Net Cash Flow (2013 - 2025)
Larimar Therapeutics (LRMR) posted Net Cash Flow of -$539000.0 for Q2 2025, up 95.54% on a QoQ basis from -$12.1 million in Q1 2025, and up 99.31% year-over-year from -$270436.6 in Q2 2024.
Larimar Therapeutics (LRMR) Net Cash Flow (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Net Cash Flow history runs 13 years deep, the most recent figure standing at -$539000.0 for Q2 2025.
- Quarterly Net Cash Flow rose 99.31% year-over-year to -$539000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$12.6 million (down 320.21% YoY) and the FY2025 annual result came in at $52.2 million, up 809.95% from the prior year.
- Net Cash Flow was -$539000.0 for Q2 2025 at Larimar Therapeutics, up from -$12.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $84.7 million in Q1 2023 and bottomed at -$77.8 million in Q2 2024.
- A 5-year average of -$6.0 million and a median of -$7.5 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2021 — Net Cash Flow sank 4781.15% — and 2023, when it jumped 1224.37%.
- Larimar Therapeutics' Net Cash Flow stood at -$1.4 million in 2021, then slumped by 4047.2% to -$59.2 million in 2022, then surged by 79.72% to -$12.0 million in 2023, then jumped by 78.51% to -$2.6 million in 2024, then soared by 79.12% to -$539000.0 in 2025.
- Business Quant data shows LRMR's Net Cash Flow at -$539000.0 in Q2 2025, -$12.1 million in Q1 2025, and -$2.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 224.46 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 57.19 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -539,000.00 |
| Jun 30, 2025 | -539,000.00 |
| Mar 31, 2025 | -12.09 Mn |
| Mar 31, 2025 | -12.09 Mn |
| Dec 31, 2024 | -2.58 Mn |
| Dec 31, 2024 | -2.58 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | -77.81 Mn |
| Jun 30, 2024 | -77.81 Mn |
| Mar 31, 2024 | 83.38 Mn |
| Mar 31, 2024 | 83.38 Mn |
| Dec 31, 2023 | -12.01 Mn |
| Dec 31, 2023 | -12.01 Mn |
| Sep 30, 2023 | -55.63 Mn |
| Sep 30, 2023 | -55.63 Mn |
| Jun 30, 2023 | -17.20 Mn |
| Jun 30, 2023 | -17.20 Mn |
| Mar 31, 2023 | 84.70 Mn |
| Mar 31, 2023 | 84.70 Mn |